華誼兄弟(300027.SZ)漲停 擬從阿里、騰訊等9戰投處募資23億
格隆匯4月29日丨華誼兄弟(300027.SZ)高開高走,目前封漲停板,報3.94元,漲停封單近40萬手,暫成交9695萬元,最新總市值110億元。公司今早發佈業績報告,全年歸屬於上市公司股東的淨利潤為虧損39.6億元。同時發佈非公開發行A股預案稱,擬以2.78元/股非公開發行合計不超過8.24億股,募集資金總額不超22.9億元。值得注意的是,本次定增引入戰投方陣容豪華,發行對象包括阿里影業、騰訊、陽光人壽等九家公司,全部發行對象均以現金方式認購。其中,阿里和騰訊系企業原已持有華誼兄弟股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.